A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Dobry stan ogólny (aktywny zawodowo lub wymagający opieki <50% czasu)
- •Oczekiwana długość życia dłuższa niż 3 miesiące
- •Niezoperacyjny zaawansowany rak jelita grubego potwierdzony badaniem histopatologicznym
- •Zmiana w genie HER2 stwierdzona w badaniu
- •Obecność co najmniej jednej mierzalnej zmiany nowotworowej
- •Gotowość stosowania antykoncepcji przez cały czas badania i 6 miesięcy po jego zakończeniu
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Wcześniejsze potwierdzenie wysokiej niestabilności mikrosatelitów (MSI-H) lub zaburzeń naprawy DNA
- •Aktywna choroba zapalna jelit w ostatnich 28 dniach
- •Inne nowotwory w ciągu ostatnich 5 lat
- •Poważne niepożądane działania poprzednich terapii, które nie ustąpiły
- •Poważna operacja lub poważna травма w ostatnich 28 dni
- •Udar mózgu, zakrzepy żył lub zatoru płucnego w ostatnich 6 miesięcy
- •Historia uzależnienia od substancji psychoaktywnych lub poważne zaburzenia psychiczne
- •Przerzuty do mózgu z objawami lub kontrolą objawów krócej niż 4 tygodnie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (31)
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Gansu Provincial Tumor Hospital
Lanzhou, China
The First People's Hospital of Foshan
Foshan, China
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Guangxi Zhuang Autonomous Region Cancer Hospital
Nanning, China
The Affiliated Hospital of Zunyi Medical University
Zunyi, China
Harbin Medical University Cancer Hospital
Harbin, China
Qiqihar First Hospital
Qiqihar, China
Henan Cancer Hospital
Zhengzhou, China
The first affiliated hospital of Zhengzhou university
Zhengzhou, China
The Third People's Hospital of Zhengzhou
Zhengzhou, China
Jingzhou First People's Hospital
Jingzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Hunan Cancer Hospital
Changsha, China
Jiangsu Provincial Cancer Hospital
Nanjing, China
Nanjing Drum Tower Hospital
Nanjing, China
Zhongda Hospital Southeast University
Nanjing, China
Jiangxi Provincal People's Hospital
Nanchang, China
Jilin Cancer Hospital
Changchun, China
The first hospital of Jilin University
Changchun, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
The First Affiliated Hospital of Air Force Medical University
Xi’an, China
The Second Affiliated Hospital of Air Force Medical University
Xi’an, China
Tianjin Union Medical Center
Tianjin, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, China
Lishui Municipal Central Hospital
Lishui, China
Trial contact
Ruihua Xu, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.